Document is current
Any future updates will be listed below
-
Authors
Papp, Kim
Balser, Sigrid https://orcid.org/0000-0002-9548-1550
Nopora, Katrin
Rewerski, Piotr
Freudensprung, Brigitte
Trieb, Michael
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04595409 at ClinicalTrials.govDocuments that mention this clinical trial
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
https://doi.org/10.1007/s12325-025-03138-2
-
Funding
Funding for this research was provided by:
Formycon AG
- License Information
-
More Information
Article History
Received: 30 November 2024
Accepted: 7 February 2025
First Online: 6 March 2025
Declarations
:
: Kim Papp has received honoraria and/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Piotr Rewerski has received honoraria as a consultant for Eli Lilly and Bayer AG. Sigrid Balser, Katrin Nopora, Brigitte Freudensprung, and Michael Trieb are employees of Formycon AG.
: The study protocol was reviewed and approved by the independent ethics committee or institutional review board for each centre.
